ANCA Associated Vasculitis, Dermatomyositis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Systemic Sclerosis
Conditions
Keywords
Systemic sclerosis, NETosis, polymorphonuclear neutrophil
Brief summary
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS). Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called NETosis. Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE. The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.
Detailed description
This study is designed to assess the role of Neutrophil Extracellular Traps (NETs) in Systemic SClerosis (SSC) as well as to evaluate the correlation between NETs production and NETs composition and the different complications and phenotypes observed in SSC. 100 SSC patients, 30 other connective tissue disease patients and 130 healthy subjects will be recruited. Blood samples will be collected to obtain plasma, serum and polynuclear neutrophils by negative selection.
Interventions
OTHERBlood sample
Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
Sponsors
CHU de Reims
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
\*For patients of group 1: * Patients with systemic sclerosis (ACR-EULAR Criteria) * Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims * Patients consenting to participate to the study * Patients enrolled in the national healthcare insurance program For patients of group 2: * Patients with other connective tissue disease (ACR specific-disease criteria) * Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims * Patients consenting to participate to the study * Patients enrolled in the national healthcare insurance program For patients of group 3 (healthy volunteers) * Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree) * Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease, * Patients without current or past neoplasy disease, * Patients without chronic metabolic pathology * Patients without treatment by anti inflammatory or corticotherapy for the last 15 days, * Patients without infectious pathology or inflammatory acute for the last 15 days * Patients consenting to participate to the study
Exclusion criteria
for patients of all groups: * Patients/Healthy volunteers under 18 years old * Patients/Healthy volunteers protected by the law * Patients/Healthy volunteers not consenting to participate to the study after information * Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion * Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantification of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls. | Day 0 | Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of the composition of Neutrophil Extracellular Traps (NETs) | Day 0 | Comparative analysis of the composition of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used. |
| Analysis of the cytokines influencing Neutrophil Extracellular Traps NETs production in vitro | Day 0 | Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils from SSC patients in vitro by differents cytokines |
Countries
France
Contacts
Primary ContactKevin DIDIER, Dr.
Outcome results
None listed